| Muscular Dystrophy, Duchenne
Emflaza vs Amondys 45
Side-by-side clinical, coverage, and cost comparison for muscular dystrophy, duchenne.Deep comparison between: Emflaza vs Amondys 45 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAmondys 45 has a higher rate of injection site reactions vs Emflaza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Amondys 45 but not Emflaza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Emflaza
Amondys 45
At A Glance
Oral
Once daily
Corticosteroid
IV infusion
Once weekly
Antisense oligonucleotide (exon 45 skipper)
Indications
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Duchenne
Dosing
Muscular Dystrophy, Duchenne 0.9 mg/kg/day once daily orally (tablets or suspension); reduce to one third of recommended dosage when used with moderate or strong CYP3A4 inhibitors; avoid use with moderate or strong CYP3A4 inducers.
Muscular Dystrophy, Duchenne 30 mg/kg once weekly as a 35 to 60-minute IV infusion via an in-line 0.2 micron filter.
Contraindications
- Known hypersensitivity to deflazacort or any of the inactive ingredients
- Known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45
Adverse Reactions
Most common (>=5%) Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, nasopharyngitis, hirsutism, central obesity, erythema, irritability, rhinorrhea, abdominal discomfort
Serious Alterations in endocrine function, immunosuppression and increased infection risk, cardiovascular/renal alterations, gastrointestinal perforation, behavioral and mood disturbances, bone effects, ophthalmic effects, serious skin rashes, growth and development effects, myopathy, Kaposi's sarcoma, thromboembolic events, anaphylaxis
Postmarketing Leukocytosis, heart failure, chorioretinopathy, corneal or scleral thinning, acute pancreatitis, peptic ulceration, edema, hypersensitivity including anaphylaxis, avascular necrosis, vertebral and long bone fractures, toxic epidermal necrolysis, thromboembolism, suicidal thoughts
Most common (>=20%) Upper respiratory tract infections, cough, pyrexia, headache, arthralgia, oropharyngeal pain
Serious Hypersensitivity reactions including angioedema and anaphylaxis
Postmarketing Infusion-related reactions including rash, headache, cough, abdominal pain, and vomiting; hypersensitivity reactions including angioedema and anaphylaxis
Pharmacology
Deflazacort is a corticosteroid prodrug whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects; the precise mechanism of therapeutic benefit in Duchenne muscular dystrophy is unknown.
Casimersen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 45 of dystrophin pre-mRNA, causing exon 45 skipping and production of an internally truncated dystrophin protein in patients with DMD mutations amenable to exon 45 skipping.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Emflaza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (0/12)
Amondys 45
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Emflaza
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (1/8) · Qty limit (0/8)
Amondys 45
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Emflaza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (1/3)
Amondys 45
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmflazaView full Emflaza profile
Amondys 45View full Amondys 45 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.